Moderna Inc (MRNA)vsMinerva Neurosciences Inc (NERV)
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
NERV
Minerva Neurosciences Inc
$4.15
-0.24%
HEALTHCARE · Cap: $223.94M
Smart Verdict
WallStSmart Research — data-driven comparison
NERV leads profitability with a 0.0% profit margin vs -141.4%. NERV earns a higher WallStSmart Score of 34/100 (F).
MRNA
Avoid21
out of 100
Grade: F
NERV
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Intrinsic value data unavailable for NERV.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Areas to Watch
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bull Case : NERV
The strongest argument for NERV centers on Debt/Equity.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Bear Case : NERV
The primary concerns for NERV are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
MRNA profiles as a turnaround stock while NERV is a value play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.11 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
MRNA generates stronger free cash flow (-563M), providing more financial flexibility.
Bottom Line
NERV scores higher overall (34/100 vs 21/100). MRNA offers better value entry with a 70.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Minerva Neurosciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of candidate products for the treatment of diseases of the central nervous system. The company is headquartered in Waltham, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?